MAPK7 Knockout HAP1 Cell Line

The choice depends on whether you are studying MAPK7 (ERK5, BMK1)'s role as an atypical MAPK with combined kinase and transactivation domains or its functions in vascular biology, shear stress response, and cancer. The Knockout line is the standard tool for asking whether ERK5 is required for these processes — ERK5 is unique among MAPKs in having a large C-terminal transactivation domain in addition to its N-terminal kinase domain; it is activated by MEK5 in response to shear stress, growth factors, and stress stimuli. Overexpression is useful for studying ERK5 in heterologous expression contexts. For ERK5 research, the EDITGENE MAPK7 Knockout in HAP1 enables study of this atypical MAPK distinct from canonical ERK1/2 signaling. Rescue with wild-type, kinase-dead (D200A), or transactivation-deficient (C-terminal deletion) ERK5 enables comprehensive structure-function studies. The knockout is a critical specificity control for ERK5 inhibitors (XMD8-92, JWG-045, BIX 02189) in cancer drug development — ERK5 has emerged as a target for combination therapy with MEK1/2 inhibitors to overcome resistance.

Primary applications: • MEK5-ERK5 signaling: phospho-ERK5 (T218/Y220) and downstream MEF2 transcription factor phosphorylation following shear stress, growth factor, or osmotic stress. • MEF2 target gene expression: MEF2-driven gene expression analysis (e.g., KLF2, c-Jun) in the ERK5-null context. • ERK5 inhibitor specificity: critical genetic control for XMD8-92, JWG-045, BIX 02189, and other ERK5 inhibitors in cancer drug development. • MEK1/2 inhibitor resistance studies: combined ERK1/2 + ERK5 pathway dependencies given ERK5's role in MEK1/2 inhibitor resistance. EDITGENE recommends this model for researchers investigating ERK5 atypical MAPK biology and combination MEK/ERK pathway-targeted cancer therapeutics.

Yes. ERK5 rescue experiments require attention to dual kinase-transactivation architecture: • Construct design: use a codon-modified MAPK7 sequence with a small C-terminal tag (FLAG, HA). ERK5 has N-terminal kinase domain with TEY activation motif and large C-terminal transactivation domain with NLS — preserve all elements. • Kinase-dead rescue: D200A mutation abolishes catalytic activity and is the standard specificity control. • Transactivation-deficient rescue: C-terminal truncation removes the transactivation domain while preserving kinase function — invaluable for distinguishing kinase-dependent from transactivation-dependent ERK5 functions. • Functional readout: rescue should restore MEF2 phosphorylation, KLF2 expression, and MEF2-driven transcription. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.